Marvin Antelman: TetraSilver TetrOxide (TSTO) — Molecular Crystal Devices, Antimicrobial Patents and the AIDS Cure Claim

This source dossier collects material on tetrasilver tetroxide (Ag₄O₄), a mixed-valence silver oxide that the chemist and inventor Marvin Antelman patented as a "molecular crystal device" capable of electrocuting pathogens. The page is a composite: patent abstracts, an independently documented preparation chemistry, a 1995 U.S. EPA efficacy review, a 2010 FDA warning letter, and a commercial advertisement offering the material for sale by the gram. It is a useful case study in how a real, well-characterized inorganic compound can carry a very large and very weakly supported therapeutic claim.

The compound itself is not in dispute. Ag₄O₄ is a dark brown-to-grey-black diamagnetic solid, a component of silver–zinc batteries, and a strong oxidizer. What is in dispute is whether it does what the patents say it does in the human body.

What the compound is

Tetrasilver tetroxide has the empirical formula AgO but is properly formulated as Ag(I)Ag(III)O₂, equivalently Ag₂O·Ag₂O₃. Each formula unit contains two monovalent silver ions and two trivalent silver ions. It is not a peroxide: it contains no O₂²⁻ ion, which is why the older names "silver peroxide" and "silver(II) oxide" are considered incorrect. Silver(III) Chemistry covers the brown Ag³⁺ ion and its hydrolysis to this oxide.

The dossier reproduces structural and physical data from Wikipedia and PubChem:

The source explicitly warns that Ag₄O₄ is not to be confused with Ag₂O (silver(I) oxide, CAS 20667-12-3, molar mass 231.74, density 7.14, melting point 280 °C, photosensitive). Both are strong oxidants; both ignite on contact with sulfur, red phosphorus, and antimony or arsenic sulfides. Ag₄O₄ reacts explosively with ammonia and hydrogen peroxide.

The dossier lists the many names under which the material has circulated: silver(II) oxide, silver(I,III) oxide, argentic oxide, Tetrasil, Sildate, Divasil, silver peroxide, silver suboxide, divalent silver oxide, mono-trivalent silver oxide, and tetrasilver tetroxide.

The "molecular crystal device" claim

Antelman's framing is that each Ag₄O₄ crystal is a molecular battery: two Ag(I) and two Ag(III) ions in a diamagnetic semiconducting lattice that, when activated by an oxidizing agent, "fires" electrons at pathogens. The dossier's own summary states the compound "works against pathogens by electrocuting, oxygenating, and chelating the target."

The mechanism is described in three parts, which Antelman groups under the term Electron Jumping Compounds (EJC):

• covalent bonding with the target;
• release of electrical energy ("nano-electrocution") through a reduction/oxidation process;
• release of highly active singlet oxygen.

See Molecular Crystal Device (Electron Jumping Compound) for the full framing, including the claimed oligodynamic ordering that the source calls the "Horsfal series" (conventionally the Horsfall series): Ag₄O₄ > Ag(III) > Ag(II) >> Ag(I).

The power-flux arithmetic

The dossier reproduces Antelman's quantitative argument, and it is worth quoting the numbers because they do not reconcile with each other.

Per molecule, two electrons are released, each with a charge of 4.8 × 10⁻¹⁰ e.s.u., approximately 1.6 × 10⁻¹⁹ coulombs. The EMF for the oxidation of Ag(I) to Ag(II) is given as 1.98 V (≈2.0 V), citing Antelman's own Encyclopedia of Chemical Electrode Potentials (Plenum, 1982), page 88. The power per electron is then:

P = E × I
2.0 × 1.6 × 10^-19 = 3.2 × 10^-19 watts per electron

The patent text (US5336499 / US5571520) instead states the crystals "release electrons equivalent to 6.4 × 10⁻¹⁹ watts per molecule." Antelman then proposes an arbitrary "power flux" metric:

Power Flux = EMF generated per molecule × Concentration × 5
             (EMF = 4.0 volts per molecular device; concentration in PPM)

Note the shift: 2.0 V in the per-electron calculation, 4.0 V in the formula. The dossier presents both without reconciling them. The resulting "power flux to effectuate 100% kills" table is reproduced below as given:

Persulfate activation

A load-bearing part of the claim is that the crystals are inert against pathogens unless activated by an oxidizing agent. Antelman compares this to the surface "etching" required to activate a photovoltaic semiconductor such as copper indium selenide. The activators named are persulfates — from DuPont's Oxone (potassium monopersulfate) to alkali peroxydisulfates — or hydrogen peroxide. See Persulfate Activation.

The dossier reports that persulfates tested alone as a control "failed to exhibit any unilateral antipathogenic activity at the optimum level selected of 10 PPM." Technical-grade TSTO is said to contain trace Oxone as activator and potassium/sodium sulfate as stabilizer.

This activation requirement sits awkwardly beside the dossier's own application instructions, which tell the user to stir TSTO in water, add a few drops of 3% hydrogen peroxide, and administer orally, nasally, dermally or rectally — while also warning "NOT FOR INJECTION" and "NOT FOR USE IN AQUARIUMS: TSTO can be toxic to fish."

Preparation chemistry

The most technically reliable material in the dossier is the preparation chemistry, which is independent of Antelman's therapeutic claims.

Hammer & Kleinberg, Inorganic Syntheses IV:12

The classical procedure oxidizes silver(I) nitrate with potassium peroxydisulfate in alkaline medium:

72 g NaOH (1.8 mol), pellets, added portionwise with stirring to 1 L water at ~85 °C
+ 75 g potassium peroxydisulfate (0.28 mol) as an aqueous slurry
+ 51 g AgNO3 (0.30 mol) dissolved in minimum water
Raise temperature to 90 °C; stir ~15 minutes
Filter the black precipitate on a large Buchner funnel
Wash with water made slightly alkaline with NaOH to remove sulfate
Air-dry
Yield: 35 g (94%)
Analysis: calculated for AgO, Ag 87.08%; found 86.93%, 86.90%
          (gravimetric chloride method, after dissolution in 3N nitric acid)

The Hammer & Kleinberg text notes that AgO does not give free hydrogen peroxide when acidified, behaves as a strongly oxidized metal ion stabilized by coordination, evolves oxygen immediately in dilute acid, and forms intensely colored solutions in concentrated acid (brown in nitric acid, olive green in sulfuric acid). The solid is stable to 100 °C, decomposes above that, is a semiconductor, and is diamagnetic.

Antelman's modified procedure (Precious Metals 16:141–149, 1992)

Stock solution: 24.0 g potassium peroxydisulfate in distilled water
              + 24.0 g sodium hydroxide
              diluted to 500 mL final volume
Vials: aliquots of silver nitrate containing 1.0 g of silver
50 mL stock heated in a 100 mL beaker to 85 °C
Add contents of one vial
Hold at 90 °C for 15 minutes
Wash and decant 4× with distilled water
Commercial comparison material: Johnson Matthey / Aesar Group,
  product code 11607, 99.9% purity, listed as silver peroxide
  and silver suboxide

The informal preparation write-up

A second, hobbyist-style account (hosted at an old university chemistry page) describes the same chemistry from the bench:

Ag+ + S2O8^2-  →  Ag3+ + 2 SO4^2-
4 Ag3+ + 6 H2O  →  2 Ag(I)Ag(III)O2 + 12 H+ + O2
4 Ag3+ + 12 OH-  →  2 Ag(I)Ag(III)O2 + 6 H2O + O2
2 Ag(I)Ag(III)O2  →  2 Ag(I)2O + O2

The write-up notes that in acidic media persulfate oxidizes Ag(I) to the brown Ag(III) ion; that Ag(III) is unstable and slowly oxidizes water, precipitating the mixed-valence oxide; that adding the brown liquid to NaOH makes the precipitation almost immediate; and that the black solid evolves oxygen in a visible "dance," rising to the surface on trapped bubbles and sinking again. It also notes that at neutral pH no brown color forms at all — the mixed oxide precipitates directly. Chloride must be avoided, since it clouds the solution as AgCl and is itself oxidized to chlorine.

The same page draws an analogy to nickel: persulfate oxidizes Ni(OH)₂ to a non-stoichiometric NiO₂·nH₂O, and silver nitrate acts as a catalyst for persulfate oxidations in acidic media via an Ag³⁺ intermediate. Both silver(III) and NiO₂ are strong enough oxidizers to take Mn(II)/Mn(IV) to permanganate and Cr(III) to dichromate.

The patent family

The dossier lists a large family of patents, all naming Antelman. They fall into rough groups.

Water treatment and bactericides (divalent/trivalent silver):

• US5017295 — Divalent Silver Bactericide for Water Treatment. Claims odorless, non-volatile control of bacteria in pool and industrial water, superior to monovalent silver because it does not decompose in light and resists halide precipitation.
• US5073382 — Divalent Silver Alkaline Bactericide Compositions. Solid alkaline compositions for food and dairy cleaners and surgical scrubbing soaps; claims 100% kills of anaerobic colonies at 100K/cc within 5 minutes.
• US5089275 — Stabilized Divalent Silver Bactericides. Ag(II) complexes entrapped in hydrated calcium sulfate; Ag(II) phosphate in phosphoric acid at a 5:2 solid:liquid ratio; claims 100% kills of E. coli within 10 minutes per EPA protocols.
• US5098582 — Divalent Silver Oxide Bactericides. Divalent silver ions in the presence of persulfate; claims no halide curdy precipitate and no skin staining.
• US5211855 — Method of Treating Water Employing Tetrasilver Tetroxide Crystals. Claims 100% kills of 100K/cc Streptococcus faecalis and E. coli in three minutes at 0.3 PPM, meeting the ten-minute EPA criterion.
• US5223149 — Trivalent Silver Water Treatment Compositions. Claims the trivalent complexes "far exceeded" EPA bacteria requirements at 1 PPM or less, and were effective without persulfates as bactericides — a notable tension with the activation requirement stated elsewhere.

The "molecular crystal device" patents:

• US5336499 / US5571520 — Molecular Crystal Device for Pharmaceuticals. The core statement of the mechanism: diamagnetic semiconducting Ag₄O₄ crystals containing two monovalent and two trivalent silver ions; activated by an oxidizing agent they release electrons equivalent to 6.4 × 10⁻¹⁹ watts per molecule (per the patent's own arithmetic), "which in effect electrocute pathogens." Claims efficacy at concentrations as low as 0.3 PPM as preservatives in cosmetics and pharmaceuticals; complete destruction of S. epidermidis at 0.6 PPM in a nutrient broth of about 1 million organisms; Candida albicans at 2.5 PPM; and the AIDS virus at 18 PPM.

The AIDS patents:

• US5676977 — Method of Curing AIDS with Tetrasilver Tetroxide Molecular Crystal Devices. Claims a single intravenous injection at about 40 PPM of human blood is sufficient; that device electrons are "triggered" by pathogens, a proliferating virus and immunity suppressing moieties (ISM); that a redox chelation mechanism produces divalent silver moieties that chelate and bind active sites; and that "a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans." The patent states the devices are "completely non-toxic" while conceding they "put stress on the liver causing hepatomegaly, but there is no loss of liver function." It also claims 100% destruction of the AIDS virus in vitro at 20 PPM.
• WO9745133 — the PCT counterpart, "Use of Tetrasilver Tetroxide Molecular Crystals in the Preparation of a Medicament for Treatment of AIDS."
• WO03043537 — Improvement in Curing AIDS with Tetrasilver Tetroxide Molecular Crystal Devices. Claims an improvement over US5676977: 15 PPM for non-terminal patients, and slow injections at 40 PPM for terminal patients "so as to reduce side effects such as benign hepatomegaly." Only a single injection is required.

Dermatology and skin:

• US6258385 — Tetrasilver Tetroxide Treatment for Skin Conditions. Claims treatment and cure of dermatitis, acne, psoriasis, herpes and skin ulcers.
• US2006105057 / US2004022868 — Compositions using tetrasilver tetroxide and methods for management of skin conditions. In one embodiment the compositions are "substantially free of added persulfates." The listed conditions include eczema, psoriasis, dermatitis, disease-induced skin ulcers, undefined tropical diseases, shingles, rashes, bedsores, cold sores, blisters, boils, herpes simplex, acne, pimples, chafing, cracking, itchiness, peeling and warts.
• US6669966 — Compositions for facilitating skin growth. Claims electron-active compounds with at least two polyvalent cations in different valence states, including Bi(III,V), Co(II,III), Cu(I,III), Fe(II,III), Mn(II,III), Pr(III,IV) and Ag(I,III) oxides, for wound dressings, burns and skin grafts.

Cancer and broader multivalent oxides:

• US6485755 — Methods of using electron active compounds for managing cancer. Also published as WO200149303 / WO200149302 / WO200149301. Claims Ag(I,III), Cu(I,III), Pr(III,IV) and Bi(III,V) oxides for systemic and external cancers, adaptable to subcutaneous, intramuscular, intravenous, infusion, transdermal or topical application.
• US6645531 / WO0149303 — Multivalent electron active compositions and methods of making and using same. The broadest statement of the Mixed-Valence Metal Oxides family.
• WO03003809 — Methods of using electron active compounds for managing conditions afflicting mammals.

Materials and textiles:

• US6436420 — High performance silver (I,III) oxide antimicrobial textile articles. Deposition or interstitial precipitation of Ag₄O₄ crystals within fibers, yarns and fabrics.
• WO0149115 — High Performance Silver (I,III) Oxide & Cobalt (II,III) Antimicrobial Textile Articles. Adds Co₃O₄.
• US20080233161 — Deposition products, composite materials and processes for the production thereof. A medical-device substrate with a deposition product consisting essentially of at least one oxidized silver species of formula Ag₇O₈X, where X is an anion.
• WO01077030 — Ozonated solutions of tetrasilver tetroxide. Claims a water disinfection method and a method for increasing the half-life of ozone in water by providing TSTO alongside the ozone.
• CN101336640 — Tetrasilver tetroxide bactericide, preparation method and use thereof. A formulation of 800–1200 parts weakly alkaline solution (pH 7.0–7.5), 0.1–0.5 parts tetrasilver tetroxide, and 8–20 parts polyvinyl alcohol as carrier, for use as a disinfection additive.

Regulatory record

EPA registration (real, and the strongest independent evidence in the dossier)

The dossier reproduces an EPA Antimicrobial Program Branch efficacy review for SILDATE, submitted by N. Jonas & Co., EPA Reg. No. 3432-AU, received 06/16/95, in 06/30/95, out 10/05/95. Key details:

• Product type: swimming pool water disinfectant.
• Active ingredient: Silver Oxide II (AgO), 2.05%; 2.73 oz silver oxide II per gallon, equivalent to 2.38 oz elemental silver per gallon.
• Activator: "Energize" (potassium persulfate), 1 pound per 10,000 gallons.
• Application rate: 1 ppm (1 oz per 10,000 gallons).
• MRID numbers: 431365-01, 434656-01, 434583-02.
• Product Manager: PM 32 (Douglas).

A separate Scorecard product profile lists SILDATE under EPA Registration Number 00343200064, used as a disinfectant, registered for unrestricted use, toxicity code 3 (Caution), with 2% silver oxide (Ag₄O₄) by mass.

The dossier also reproduces the toxicology summary for the 2% active-ingredient product:

• Acute Oral Toxicity: LD₅₀ greater than 5,000 mg/kg
• Acute Dermal Toxicity: LD₅₀ greater than 2,000 mg/kg
• Primary Eye Irritation: mildly irritating
• Primary Skin Irritation: no irritation
• Skin Sensitization: non-sensitizing
• Toxicity Category III (Caution) for the 2% product; Category IV for supporting studies
• Practically non-toxic to avian species; highly toxic to aquatic species
• Does not hydrolyze

The dossier states a 3% concentrate was evaluated by a certified laboratory under Good Laboratory Practice per the Code of Federal Regulations.

FDA warning (2010)

The dossier notes that in 2010 the FDA issued a warning letter to Aidance Skincare and Topical Solutions, LLC concerning the firm's marketing of Tetrasil and Genisil ointments of tetrasilver tetroxide for herpes and similar conditions. This is a direct regulatory contradiction of the therapeutic claims made in the patents and in the dossier's own advertisement.

The "14 labs" claim

The dossier asserts that TSTO "was tested by 14 independent research labs against gram-negative bacteria, gram-positive bacteria, fungi, yeast, and viruses," naming Quintiles, Parexel, MDS/Pharma "and other renowned research organizations." No report, protocol, or result from any of these organizations is reproduced anywhere in the document. The claim should be treated as an assertion, not as evidence.

Nomenclature and the Tudela correction

The dossier includes David Tudela's 2008 Journal of Chemical Education paper, "Silver(II) Oxide or Silver(I,III) Oxide?" (J. Chem. Educ. 2008, 85(6), 863, doi:10.1021/ed085p863). Tudela argues via a thermochemical cycle with volume-based lattice energies that the mixed-valence silver(I,III) oxide is more stable than a hypothetical silver(II) oxide, and relates the coordination geometries of silver and copper in their oxides to their electron configurations. The dossier cites this precisely to resolve the naming confusion — yet continues to use "silver(II) oxide" in places, including in the EPA review's own active-ingredient line.

The dossier also reproduces a set of older silver oxide references: Johnston, Cuta & Garrett, "The Solubility of Silver Oxide in Water, in Alkali and in Alkaline Salt Solutions," JACS 55(6), 2311–2325 (1933); a 1926 J. Phys. Chem. note on silver oxide solubility; a 1944 J. Chem. Educ. piece on the oxidation states of silver; Herley & Prout, "The Thermal Decomposition of Silver Oxide," JACS 82(7), 1540–1543 (1960); and Sproul on electronegativity scales, J. Phys. Chem. 98(27), 6699–6703 (1994).

Oxone and potassium peroxymonosulfate

The activator chemistry is documented in the dossier via the Wikipedia entry on potassium peroxymonosulfate. Oxone (DuPont) and Caroat (Evonik, formerly Degussa) are trade names for the potassium salt of peroxymonosulfuric acid, supplied as a triple salt 2KHSO₅·KHSO₄·K₂SO₄ (CAS 37222-66-5, molecular weight 614.76, water solubility 250 g/L at 20 °C). The standard electrode potential is +1.44 V:

HSO5- + 2 H+ + 2 e-  →  HSO4- + H2O

Oxone oxidizes aldehydes to carboxylic acids (and to esters in alcoholic solvents), cleaves internal alkenes, epoxidizes terminal alkenes, converts thioethers to sulfones, tertiary amines to amine oxides, and phosphines to phosphine oxides. It is used in swimming pools to keep water clear so that chlorine can sanitize rather than clarify.

Limitations and unresolved tensions

The dossier contains several internal contradictions that it does not adjudicate:

1. Arithmetic. EMF is given as 1.98 V (≈2.0 V) in one passage and 4.0 V in the power-flux formula. Power output is given as 3.2 × 10⁻¹⁹ W per electron and 6.4 × 10⁻¹⁹ W per molecule. These are not reconciled.
2. "Completely non-toxic" vs. hepatomegaly. The AIDS patent claims the devices are "completely non-toxic" while conceding they cause hepatomegaly.
3. "No interactions with other medications" vs. strong oxidizer. The dossier claims no drug interactions, yet also states TSTO reacts explosively with ammonia and hydrogen peroxide.
4. Patent claims vs. FDA warning. The patents claim cures for herpes and AIDS; the FDA warned a marketer against exactly those claims.
5. "14 independent labs" vs. no reports. The claim is asserted; no report is reproduced.
6. Activation requirement vs. no-persulfate claims. US5223149 claims trivalent silver complexes were effective without persulfates, while the core mechanism claim requires an oxidizing activator. US2006105057 describes dermatological compositions "substantially free of added persulfates."
7. Nomenclature. The dossier warns against confusing Ag₄O₄ with Ag₂O, and cites Tudela to correct the "silver(II) oxide" name, but still uses the incorrect name in places.
8. Informal preparation account. The second preparation write-up is a hobbyist web page with a YouTube link and a self-experiment anecdote about athlete's foot, not a peer-reviewed procedure.

Related work and cross-references

• Marvin Antelman — the inventor and sole named patentee.
• Tetrasilver Tetroxide (Ag₄O₄) — the compound itself.
• Molecular Crystal Device (Electron Jumping Compound) — the "electron jumping compound" / "molecular battery" framing.
• Persulfate Activation — the oxidizing-agent activation requirement.
• Mixed-Valence Metal Oxides — the broader Ag/Cu/Pr/Bi/Co/Fe/Mn family.
• Silver(III) Chemistry — the brown Ag³⁺ ion and its hydrolysis.
• Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence — patent claims vs. EPA registration vs. FDA warning vs. absence of clinical data.
• concepts-chemistry and concepts-health — topic guides this source extends.